US OptionsDetailed Quotes
VIR250516P2500
- 0.05
- 0.000.00%
15min DelayClose Apr 30 16:00 ET
0.00High0.00Low
0.05Open0.05Pre Close0 Volume33 Open Interest2.50Strike Price0.00Turnover270.14%IV59.97%PremiumMay 16, 2025Expiry Date0.00Intrinsic Value100Multiplier16DDays to Expiry0.05Extrinsic Value100Contract SizeAmericanOptions Type-0.0302Delta0.0199Gamma122.40Leverage Ratio-0.0073Theta-0.0001Rho-3.70Eff Leverage0.0009Vega
Vir Biotechnology Stock Discussion
Brii Bio Secures 4-Year Cash Runway Despite Wider Losses: Key HBV Trial Success
Benzinga· 1 min ago
First patient enrolled in ECLIPSE 1 Phase 3 clinical trial evaluating combination of tobevibart and elebsiran for chronic suppressive treatment
ECLIPSE program designed to enable regulatory submissions and support reimbursement and access
Rapid study start indicative of significant unmet need for chronic hepatitis delta treatment
Major Breakthrough: Vir Biotech Advances First-Ever US Treatment for Deadly Hepatitis Delta
They don't simply give such a high price target for nothing.
$Vir Biotechnology (VIR.US)$
Congratulations to trader who have bought it on premarket for day trade profit.
Market is going downtrend for the incoming fed announcement. Lock on profit today as tomorrow market will be closed.
Today good opportunity to swing trade $ $Sana Biotechnology (SANA.US)$ $Absci Corp (ABSI.US)$
Pick the right momentum stock to trade for profit.
Follow me, follow momentum
No comment yet